Trial Profile

Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Durvalumab (Primary) ; Ramucirumab (Primary) ; Rucaparib (Primary) ; Trastuzumab
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms PLATFORM

Most Recent Events

02 Sep 2024 Status changed from recruiting to active, no longer recruiting.
20 Jan 2024 Results(n=24) presented at the 2024 Gastrointestinal Cancers Symposium
24 Oct 2023 Interim results (at data cut-off 28 April 2023, n=125) presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com